Superiority of the triple comb. of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplant. The MMVAR/IFM 2005-04 randomized phase III trial from the chron. leukemia working party of the Europ. Grp. for Blood/Marrow Transplant. (Jnl. of Clin. Oncol. (2012) 30 (2475-2482))

[No Value] Garderet, Francesco Onida

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)3429
Number of pages1
JournalJournal of Clinical Oncology
Issue number27
Publication statusPublished - Sep 20 2012

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this